We envision a world where
DISEASES DRIVEN BY
INFLAMMATION
are treatable at their source

Targeting the NLRP3 inflammasome

OUR DIFFERENTIATED APPROACH

We are experienced biotech innovators with a vision to make chronic inflammatory disease treatable at its source. Our approach is built on the mounting body of scientific evidence supporting the NLRP3 inflammasome as the upstream catalyst and key driver of inflammation – a biological cascade that drives many chronic diseases of the body and brain.

science
Headshot of Alan Watt, PhD, MBA, Chief Scientific Officer of NodThera.”

With an advanced suite of tools in our arsenal, a deep pipeline and an unparalleled team of experts guiding our approach, NodThera is leading the charge in targeting the NLRP3 inflammasome to usher in a new era of anti-inflammatory therapeutics

Alan Watt, PhD, MBA
Interim Chief Executive Officer

Meet the experts

The NodThera team is led by masters of their craft – industry leaders with the right mix of creativity, imagination, skill and expertise that will bring the potential of NLRP3-targeting medicines to life.
about us

To unlock the potential of NLRP3 inflammasome inhibition means we will be able to deliver viable medicines to millions of patients suffering from chronic inflammatory diseases.

white 3D render of heart with orange shading in the center indicating inflammation.

Cardiovascular Disease

white 3D render of knee bone with orange shading at the joint indicating inflammation.

Osteoarthritis

white 3D render of brain with orange shading at the center indicating inflammation.

Neuroinflammation

Explore our portfolio

OF NLRP3 INFLAMMASOME INHIBITORS

pipeline

Join us in leading the charge

careers